Lifeward Ltd. (LFWD) reported a first-quarter net loss of $10.8 million and a 22% decline in revenue, leading the company to delay the filing of its quarterly report to finalize accounting for a recent strategic transaction.
“During the first quarter, we significantly strengthened Lifeward’s strategic and financial position through the successful closing of our strategic transaction and financing, marking an important milestone in our evolution,” said Mark Grant, CEO of Lifeward.
The biomedical firm’s loss of $6.70 per share was substantially wider than the Zacks Consensus Estimate of a $0.34 loss. The increased net loss was driven by a one-time, non-cash research and development expense of approximately $4.9 million related to the acquisition of Oratech.
Revenue for the first quarter of 2026 was $3.9 million, a decrease from $5.0 million in the same period of 2025. The decline was primarily caused by a 38% drop in sales of AlterG anti-gravity systems, which the company attributed to working capital constraints impacting its supply chain. Sales of ReWalk Personal exoskeletons, however, increased by 11% to $1.6 million.
Despite the wider loss, Lifeward’s liquidity improved. The company held $11.4 million in cash as of March 31, up from $2.2 million at the end of 2025. The increase was driven by net proceeds from a financing transaction and $6.5 million in cash acquired through the Oratech deal.
The results signal that while the company's core operations face headwinds, its recent strategic moves have shored up its balance sheet. Investors will be watching for the delayed Form 10-Q filing for further details on the Oratech transaction's financial impact and for signs of recovery in AlterG sales in the coming quarters.
This article is for informational purposes only and does not constitute investment advice.
